Tumors as elusive targets of T-cell-based active immunotherapy

Trends in Immunology

Volumn 24, Issue 6, 2003, Pages 334-341

  Marincola, Francesco M ^a   Wang, Ena ^a   Herlyn, Meenhard ^b   Seliger, Barbara ^c   Ferrone, Soldano ^d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b WISTAR INSTITUTE   (United States)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; CANCER VACCINE; LYMPHOCYTE ANTIGEN RECEPTOR;

ACTIVE IMMUNIZATION; ANTIGEN SPECIFICITY; CANCER CELL; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL TRIAL; HOST; HUMAN; IMMUNE RESPONSE; IMMUNOASSAY; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; IMMUNOREACTIVITY; LYMPHOCYTOPOIESIS; MEDIATOR; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TARGET ORGAN; TUMOR; TUMOR CELL; TUMOR IMMUNITY; TUMOR LOCALIZATION; TUMOR REJECTION; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; NEOPLASM;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 0038519360     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4906(03)00116-9     Document Type: Review

References (67)

1. Boon T., et al. Tumor antigens recognized by T cells. Immunol. Today. 18:1997;267-268.
2. Old L.J., Chen Y.T. New paths in human cancer serology. J. Exp. Med. 187:1998;1163-1167.
3. Kawakami Y., Rosenberg S.A. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. Int. Rev. Immunol. 14:1997;173-192.
4. Rosenberg S.A., et al. Immunologic and therapeutic evaluation of a synthetic tumor associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:1998;321-327.
5. Marchand M., et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer. 80:1999;219-230.
6. Lau R., et al. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother. 24:2001;66-78.
7. Panelli M.C., et al. Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma associated antigens MART-1 and gp100. J. Immunother. 23:2000;487-498.
8. Jager D., et al. Vaccination for malignant melanoma: recent developments. Oncology. 60:2001;1-7.
9. Nestle F.O., et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
10. Cormier J.N., et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J. Sci. Am. 3:1997;37-44.
11. Alexander-Miller M.A., et al. Role of antigen, CD8, and cytotoxic T lymphocyte (CTL) avidity in high dose antigen induction of apoptosis of effector CTL. J. Exp. Med. 184:1996;485-492.
12. Toes R.E., et al. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156:1996;3911-3918.
13. Viola A., Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 273:1996;104-106.
14. Alexander-Miller M.A., et al. Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor α receptor II-mediated apoptosis of cytotoxic T lymphocytes. J. Exp. Med. 188:1998;1391-1399.
15. *0201 binding residues. J. Immunol. 157:1996;2539-2548.
16. Salgaller M.L., et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:1996;4749-4757.
17. Monsurro V., et al. Kinetics of TCR use in response to repeated epitope-specific immunization. J. Immunol. 166:2001;5817-5825.
18. Perez-Diez A., et al. Intensity of the vaccine-elicited immune response determines tumor clearance. J. Immunol. 168:2002;338-347.
19. Romero P., et al. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med. 188:1998;1641-1650.
20. Lee P.P., et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5:1999;677-685.
21. Pittet M.J., et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 190:1999;705-715.
22. Lee K.H., et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J. Immunol. 163:1999;6292-6300.
23. + T-cell maturation: CD27 might provide a clue. Trends Immunol. 23:2002;586-591.
24. + T cells in acute infectious mononucleosis. Nat. Med. 2:1996;906-911.
25. Greten T.F., et al. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc. Natl. Acad. Sci. U. S. A. 95:1998;7568-7573.
26. Bieganowska K., et al. Direct analysis of viral-specific CD8(+) T cells with soluble HLA-A2/Tax 11-19 tetramer complexes in patients with human T cell lymphotropic virus-associated myelopathy. J. Immunol. 162:1999;1765-1771.
27. + T cells. J. Immunol. 165:2000;2287-2296.
28. Appay V., et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192:2000;63-75.
29. + T cells. J. Immunol. 168:2002;5933-5942.
30. Kaech S.M., et al. Molecular and functional profiling of memory CD8 T cell differentiation. Cell. 111:2002;837-851.
31. Khong H.T., Restifo N.P. Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nat. Immunol. 3:2002;999-1005.
32. Jager E., et al. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int. J. Cancer. 71:1997;142-147.
33. Ferrone S., Marincola F.M. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today. 16:1995;487-494.
34. Garrido F., et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today. 18:1997;89-95.
35. Hicklin D.J., et al. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today. 5:1999;178-186.
36. Marincola F.M., et al. Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 74:2000;181-273.
37. Lee K.H., et al. Functional dissociation between local and systemic immune response following peptide vaccination. J. Immunol. 161:1998;4183-4194.
38. Kammula U.S., et al. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. J. Immunol. 163:1999;6867-6879.
39. Panelli M.C., et al. Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases. J. Immunol. 164:2000;495-504.
40. 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. augmentation with cyclophosphamide and correlation with response. Cancer. 73:1994;1731-1737.
41. Matzinger P. Tolerance, danger, and the extended family. Annu. Rev. Immunol. 12:1994;991-1045.
42. Fuchs E.J., Matzinger P. Is cancer dangerous to the immune system? Semin. Immunol. 8:1996;271-280.
43. Ochsenbein A.F., et al. Immune suerveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. U. S. A. 96:1999;2233-2238.
44. Gervois N., et al. Suboptimal activation of melanoma infiltrating lymphocytes (TIL) due to low avidity of TCR/MHC-tumor peptide interactions. J. Exp. Med. 183:1996;2403-2407.
45. Valitutti S., et al. Different responses are elicited in cytotoxic T lymphocytes by different levels of T cell receptor occupancy. J. Exp. Med. 183:1996;1917-1921.
46. Wilson B.S., et al. DR (Ia-like) antigens on human melanoma cells. serological detection and immunochemical characterization. J. Exp. Med. 149:1979;658-668.
47. Lollini P.L., Forni G. Cancer immunoprevention: tracking down persistent tumor antigens. Trends Immunol. 24:2003;62-66.
48. Riker A., et al. Immune selection following antigen specific immunotherapy of melanoma. Surgery. 126:1999;112-120.
49. Cormier J.N., et al. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int. J. Cancer. 75:1998;517-524.
50. Wang E., Marincola F.M. A natural history of melanoma: serial gene expression analysis. Immunol. Today. 21:2000;619-623.
51. Ohnmacht G.A., et al. Short term kinetics of tumor antigen expression in response to vaccination. J. Immunol. 167:2001;1809-1820.
52. Wang E., et al. High fidelity mRNA amplification for gene profiling using cDNA microarrays. Nat. Biotechnol. 17:2000;457-459.
53. Wang E., et al. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res. 62:2002;3581-3586.
54. Brown P.O., Botstein D. Exploring the new world of the genome with DNA microarrays. Nat. Genet. 21:1999;33-37.
55. Mocellin S., et al. Kinetics of cytokine expression in melanoma metastases classifies immune responsiveness. Int. J. Cancer. 93:2001;236-242.
56. Mocellin S., et al. The dual role of IL-10. Trends Immunol. 24:2003;36-43.
57. Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13:1995;399-415.
58. Rosenberg S.A., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. Med. Assoc. 271:1994;907-913.
59. Richmond A., et al. Molecular characterization and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to β-thromboglobulin. EMBO J. 7:1988;2025-2033.
60. Schwab E.D., Pienta K.J. Cancer as a complex adaptive system. Med. Hypotheses. 47:1996;235-241.
61. Cucuianu A. Chaos in cancer? Nat. Med. 4:1998;1342-1343.
62. Dalgleish A. The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines. QJM. 92:1999;347-359.
63. Papac R.J. Spontaneous regression of cancer: possible mechanisms. In Vivo. 12:1998;571-578.
64. Sallusto F., et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:1999;659-660.
65. Champagne P., et al. Skewed maturation of memory HIV-specific CD8 T lymphoctes. Nature. 410:2001;106-111.
66. Jager E., et al. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int. J. Cancer. 66:1996;470-476.
67. Yee C., et al. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162:1999;2227-2234.